Drug Abuse Test Manufacturers May Benefit From Revised Federal Standards
This article was originally published in The Gray Sheet
Executive Summary
The House Energy & Commerce Committee will explore and promote alternative technologies for drugs-of-abuse testing in the workplace, according to Alan Slobodin, deputy chief counsel for oversight
You may also be interested in...
Testing The Limits? FDA Drugs Of Abuse Guidance Draws Mixed Reaction
On-site testing manufacturers once again are questioning FDA's regulatory authority regarding on-site drugs of abuse tests intended for non-medical purposes
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.